


# Using OFF-X with MetaCore

## Exploring safety concerns behind your target of interest


OFF-X is Clarivate’s translational safety intelligence portal (separate subscription required). Combine it with MetaCore to anticipate safety liabilities of potential drug targets that you have identified using MetaCore.

**Use Case**, using public dataset GSE95153, we explore the biological rationale behind combining BET and MEK inhibitors for NRAS-mutant melanoma.

**Upload and analyse** your ‘omics data into MetaCore to understand the biological processes and hypothesize potential drug targets





Pathway map enrichment shows combination BET + MEK inhibition act synergistically to suppress Aurora B kinase expression.



Network analysis identifies the transcription factor VDRIP as a potential driver of the synergistic drug effect

Click on the drug target MEK-1 to learn more about what it does; and **link to OFF-X targets**:

 **MEK1(MAP2K1)**

Network object |  [Build Network](#)

	Human	Mouse	Rat
<b>Clarivate Links</b>			
Cortellis Drug Discovery Intelligence	<a href="#">mitogen-activated protein kinase kinase 1</a>		
<b>Clarivate OFF-X Links</b>			
OFF-X Safety alerts	<a href="#">MEK1, ( 3784 alerts )</a>		

**Welcome to OFF-X™**

If you already have a user name and password for OFF-X please use the login option below:

**USERNAME**

**PASSWORD**

**LOGIN**

If you are already a registered user of OFF-X and your organization has OFF-X Single Sign-On access (SSO), please click here:

**SSO LOGIN**

By logging in you are accepting the following [Terms & Conditions](#). (Last updated September 2021)

Forgot your password? Please [click here](#)

- If you are not yet a subscriber, please contact OFF-X support [using this form](#)
- If your organization has licensed OFF-X under a self-registration mode, [click here](#) to register


- Login,
- Self-register, or
- Request more information

From the **OFF-X safety portal** you can:

- Anticipate safety liabilities for your target of interest
- Track safety concerns over time
- Explore competitor product safety profiles

Three dashboards that you might be interested in checking out initially are:


a. A heatmap of adverse events, grouped by therapeutic area / organ class:



b. The Translatability dashboard showing level of evidence from preclinical and clinical studies:

OFF-X TARGET/ CLASS SCORE	SOC	BIOLOGICAL ROLE & PRECLINICAL PHARMACOLOGICAL EVIDENCE					CLINICAL PHARMACOLOGICAL EVIDENCE													
		TARGET EXPRESSION <small>Source: Human Protein Atlas</small>	HUMAN GENETIC VARIANTS	KNOCKOUT/ KNOCKDOWN ANIMAL DATA	IN VITRO DATA / PATIENTS SAMPLE	PRECLINICAL	PHASE I	PHASE II	PHASE III	CLINICAL REGULATORY	POST- MARKETING	PHASE NOT SPECIFIED								
	All System Organ Classes	24	1	0	27	418	544	1360	124	533	349	583								
Very High Evidence	Investigations				1	87	52	202	12	71	20	41								
Very High Evidence	Gastrointestinal disorders					51	95	216	28	84	47	83								
Low Evidence	Reproductive system and breast disorders					34	1	7		9		1								

c. Safety maps:



Particularly useful for novel drug targets (not the case here) where there is no safety information; these maps show class alerts for neighboring targets, helping you to anticipate possible safety liabilities.



**For more information about OFF-X, please check:**

The OFF-X information page: **OFF X**  
**([targetssafety.info](https://targetssafety.info))**

Request a trial: **Sales Enquiries - Clarivate**  
Contact your Clarivate account manager

**For additional support please contact  
Clarivate customer support at:**

**<https://support.clarivate.com/LifeSciences>**

Where you will find links to email, chat, call  
us, or to open a case online

**[clarivate.com](https://clarivate.com)**